TY - JOUR
T1 - N-acetylcysteine in severe falciparum malaria in Thailand
AU - Treeprasertsuk, Sombat
AU - Krudsood, Srivicha
AU - Tosukhowong, Thanawat
AU - Maek-A-Nantawat, Wirach
AU - Vannaphan, Suparp
AU - Saengnetswang, Tosaporn
AU - Looareesuwan, Sornchai
AU - Kuhn, Walter F.
AU - Brittenham, Gary
AU - Carroll, James
PY - 2003/3
Y1 - 2003/3
N2 - One hundred and eight patients with severe falciparum malaria underwent a placebo controlled trial with the antioxidant, N-acetylcysteine (NAC), as an adjunctive therapy along with standard intravenous artesunate therapy. Three NAC dosage regimens were used: an intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours intravenously for up to 18 doses (Group 1); a single intravenous loading dose followed by oral NAC in the same amount as for Group 1 (Group 2); a regimen identical to Group 1 except that oral NAC was administered after the first 24 hours (Group 3). Fifty-four patients received placebo plus artesunate. Two critically ill patients died in Group 1. No patient sustained an adverse reaction to the NAC other than vomiting, and the deaths were attributed to severe disease with multiple organ involvement. The excellent results with NAC, the lack of adverse effects, and the rationale for NAC benefit supports the need for a large, double blind trial of NAC as an adjunctive therapy for severe malaria.
AB - One hundred and eight patients with severe falciparum malaria underwent a placebo controlled trial with the antioxidant, N-acetylcysteine (NAC), as an adjunctive therapy along with standard intravenous artesunate therapy. Three NAC dosage regimens were used: an intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours intravenously for up to 18 doses (Group 1); a single intravenous loading dose followed by oral NAC in the same amount as for Group 1 (Group 2); a regimen identical to Group 1 except that oral NAC was administered after the first 24 hours (Group 3). Fifty-four patients received placebo plus artesunate. Two critically ill patients died in Group 1. No patient sustained an adverse reaction to the NAC other than vomiting, and the deaths were attributed to severe disease with multiple organ involvement. The excellent results with NAC, the lack of adverse effects, and the rationale for NAC benefit supports the need for a large, double blind trial of NAC as an adjunctive therapy for severe malaria.
UR - http://www.scopus.com/inward/record.url?scp=0042066708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042066708&partnerID=8YFLogxK
M3 - Article
C2 - 12971512
AN - SCOPUS:0042066708
SN - 0125-1562
VL - 34
SP - 37
EP - 42
JO - Southeast Asian Journal of Tropical Medicine and Public Health
JF - Southeast Asian Journal of Tropical Medicine and Public Health
IS - 1
ER -